BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34323034)

  • 1. [Construction and Anti-tumor Effect Evaluation of a Dual-Responsive Hyaluronic Acid Carbon Quantum Dot-Gelatin Nano-Drug Delivery System].
    Li M; Li JP; Wang YS; He Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 52(4):577-584. PubMed ID: 34323034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid pH-responsive self-disintegrating nanoassemblies balance tumor accumulation and penetration for enhanced anti-breast cancer therapy.
    Li J; Wang Y; Xu C; Yu Q; Wang X; Xie H; Tian L; Qiu Y; Guo R; Lu Z; Li M; He Q
    Acta Biomater; 2021 Oct; 134():546-558. PubMed ID: 33882357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin-mediated active tumor targeting and tumor microenvironment response dendrimer-gelatin nanoparticles for drug delivery and tumor treatment.
    Hu G; Zhang H; Zhang L; Ruan S; He Q; Gao H
    Int J Pharm; 2015 Dec; 496(2):1057-68. PubMed ID: 26598487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
    Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
    Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release.
    Ruan S; Cao X; Cun X; Hu G; Zhou Y; Zhang Y; Lu L; He Q; Gao H
    Biomaterials; 2015 Aug; 60():100-10. PubMed ID: 25988725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment.
    Zhang X; Zhao M; Cao N; Qin W; Zhao M; Wu J; Lin D
    Biomater Sci; 2020 Mar; 8(7):1885-1896. PubMed ID: 32022813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photothermal/matrix metalloproteinase-2 dual-responsive gelatin nanoparticles for breast cancer treatment.
    Chen X; Zou J; Zhang K; Zhu J; Zhang Y; Zhu Z; Zheng H; Li F; Piao JG
    Acta Pharm Sin B; 2021 Jan; 11(1):271-282. PubMed ID: 33532192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Size-shrinkable and protein kinase Cα-recognizable nanoparticles for deep tumor penetration and cellular internalization.
    Ma JB; Shen JM; Yue T; Wu ZY; Zhang XL
    Eur J Pharm Sci; 2021 Apr; 159():105693. PubMed ID: 33383133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid/Hyaluronic Acid-Coated Doxorubicin-Fe
    Liang J; Yang X; Liu D; Cong M; Song Y; Bai S
    AAPS PharmSciTech; 2020 Aug; 21(6):235. PubMed ID: 32803528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma.
    Ruan S; He Q; Gao H
    Nanoscale; 2015 Jun; 7(21):9487-96. PubMed ID: 25909483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA.
    Wang T; Yu X; Han L; Liu T; Liu Y; Zhang N
    Int J Nanomedicine; 2017; 12():4773-4788. PubMed ID: 28740384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
    Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
    Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid-coated single-walled carbon nanotubes loaded with doxorubicin for the treatment of breast cancer.
    Liu D; Zhang Q; Wang J; Fan L; Zhu W; Cai D
    Pharmazie; 2019 Feb; 74(2):83-90. PubMed ID: 30782256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy.
    Fang J; Zhang S; Xue X; Zhu X; Song S; Wang B; Jiang L; Qin M; Liang H; Gao L
    Int J Nanomedicine; 2018; 13():5113-5126. PubMed ID: 30233175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual size/charge-switchable and multi-responsive gelatin-based nanocluster for targeted anti-tumor therapy.
    Xiao R; Ye J; Li X; Wang X
    Int J Biol Macromol; 2023 May; 238():124032. PubMed ID: 36921812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-responsive Sulfated Hyaluronic Acid Nanoparticles Targeting Tumor Cells and CAFs for the Treatment of Breast Cancer.
    Wang D; Wu J; Qi C; Dong J; Ding X; Yu G; Liu S; Zhang B; Gao Z; Wei X; Liu H
    Recent Pat Anticancer Drug Discov; 2022; 18(2):200-210. PubMed ID: 35538821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies.
    Jamshidi Z; Sadat Zavvar T; Ramezani M; Alibolandi M; Hadizadeh F; Abnous K; Taghdisi SM
    Int J Pharm; 2022 Jul; 623():121892. PubMed ID: 35671850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.